{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:37Z","timestamp":1778780137298,"version":"3.51.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1339,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>There is currently no consensus on the most suitable treatment for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation. This open, multicenter, retrospective, uncontrolled cohort study was designed to evaluate the safety and preliminary efficacy of the combined use of a mammalian target of rapamycin (mTOR) inhibitor and sorafenib in this setting. In 31 patients who suffered from HCC recurrence after liver transplantation, the immunosuppressive therapy was changed to mTOR inhibitors, and systemic treatment with sorafenib was initiated. This combination was maintained until symptomatic tumor progression, death, hepatic decompensation, or unacceptable toxicity occurred. Primary treatment efficacy was determined by overall survival and progression-free survival, and secondary efficacy was determined by the overall response rate. Toxicity parameters associated with the use of sorafenib and mTOR inhibitors were also analyzed. The overall response rate according to the Response Evaluation Criteria in Solid Tumors was 3.8% (1\/26), and there was sustained stabilization of the disease in 13 additional cases (50.0%). The median overall survival was 19.3 months [95% confidence interval (CI) = 13.4\u201325.1 months], and the median time to progression was 6.77 months (95% CI = 2.3\u201311.1 months). Only 2 grade 3\/4 cases of hyperglycemia and 1 case of grade 3\/4 mucositis were reported, and they were possibly related to mTOR inhibitors. The most common severe adverse event probably related to sorafenib was diarrhea (12.9%). In conclusion, the coadministration of sorafenib and an mTOR inhibitor could be effective despite notable toxicity in patients with post\u2013liver transplant HCC recurrence not suitable for radical therapy. The toxicity and efficacy need to be further evaluated in randomized controlled studies for this combination to be considered a valid option.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22434","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T19:14:29Z","timestamp":1316459669000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":143,"title":["Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"Carlos","family":"Gomez-Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier F.","family":"Castroagudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Testillano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Matilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20250124","first-page":"817823","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.","volume":"139","author":"ElSerag","year":"2003","journal-title":"Ann Intern Med"},{"key":"R3-7-20250124","doi-asserted-by":"crossref","first-page":"13191326","DOI":"10.1097\/00007890-200405150-00002","article-title":"Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.","volume":"77","author":"Koehl","year":"2004","journal-title":"Transplantation"},{"key":"R4-7-20250124","doi-asserted-by":"crossref","first-page":"128135","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"R5-7-20250124","doi-asserted-by":"crossref","first-page":"15651572","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"R6-7-20250124","doi-asserted-by":"crossref","first-page":"335348","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy.","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R7-7-20250124","doi-asserted-by":"crossref","first-page":"715722","DOI":"10.1007\/s00432-008-0506-z","article-title":"Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma.","volume":"135","author":"Wang","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"R8-7-20250124","doi-asserted-by":"crossref","first-page":"633638","DOI":"10.1002\/lt.21420","article-title":"Sirolimusbased immunosuppression following liver transplantation for hepatocellular carcinoma.","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Liver Transpl"},{"key":"R9-7-20250124","doi-asserted-by":"crossref","first-page":"11621168","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimusbased immunosuppression after liver transplantation for hepatocellular carcinoma: longterm outcomes and side effects.","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"R10-7-20250124","doi-asserted-by":"crossref","first-page":"275280","DOI":"10.1016\/j.ejso.2009.10.001","article-title":"Longterm survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.","volume":"36","author":"Kornberg","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"R11-7-20250124","doi-asserted-by":"crossref","first-page":"660662","DOI":"10.1016\/j.transproceed.2010.02.014","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation.","volume":"42","author":"Valdivieso","year":"2010","journal-title":"Transplant Proc"},{"key":"R12-7-20250124","doi-asserted-by":"crossref","first-page":"904152","DOI":"10.1155\/2010\/904152","article-title":"Prognostic factors for tumor recurrence after a 12year, singlecenter experience of liver transplantations in patients with hepatocellular carcinoma.","volume":"2010","author":"Cescon","year":"2010","journal-title":"J Transplant"},{"key":"R13-7-20250124","doi-asserted-by":"crossref","first-page":"227231","DOI":"10.1097\/TP.0b013e3181c3c540","article-title":"Effect of different immunosuppressive schedules on recurrencefree survival after liver transplantation for hepatocellular carcinoma.","volume":"89","author":"Vivarelli","year":"2010","journal-title":"Transplantation"},{"key":"R14-7-20250124","doi-asserted-by":"crossref","first-page":"378390","DOI":"10.1056\/NEJMoa0708857","article-title":"; for SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-7-20250124","doi-asserted-by":"crossref","first-page":"771775","DOI":"10.1016\/j.jhep.2010.01.025","article-title":"Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.","volume":"52","author":"Bhoori","year":"2010","journal-title":"J Hepatol"},{"key":"R16-7-20250124","doi-asserted-by":"crossref","first-page":"725733","DOI":"10.1016\/j.jhep.2009.03.028","article-title":"Ras pathway activation in hepatocellular carcinoma and antitumoral effect of combined sorafenib and rapamycin in vivo.","volume":"51","author":"Newell","year":"2009","journal-title":"J Hepatol"},{"key":"R17-7-20250124","doi-asserted-by":"crossref","first-page":"51245130","DOI":"10.1158\/1078-0432.CCR-07-4774","article-title":"Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.","volume":"14","author":"Wang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R19-7-20250124","doi-asserted-by":"crossref","first-page":"205216","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R20-7-20250124","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1007\/PL00009947","article-title":"Pattern and management of recurrent hepatocellular carcinoma after liver transplantation.","volume":"5","author":"Regalia","year":"1998","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R21-7-20250124","doi-asserted-by":"crossref","first-page":"534540","DOI":"10.1002\/lt.20128","article-title":"Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis.","volume":"10","author":"Roayaie","year":"2004","journal-title":"Liver Transpl"},{"key":"R22-7-20250124","doi-asserted-by":"crossref","first-page":"22832289","DOI":"10.1245\/s10434-010-0999-y","article-title":"Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.","volume":"17","author":"Taketomi","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R23-7-20250124","doi-asserted-by":"crossref","first-page":"324331","DOI":"10.1200\/JCO.1999.17.1.324","article-title":"Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation.","volume":"17","author":"Schlitt","year":"1999","journal-title":"J Clin Oncol"},{"key":"R24-7-20250124","doi-asserted-by":"crossref","first-page":"8182","DOI":"10.1002\/lt.500050111","article-title":"De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis.","volume":"5","author":"Saxena","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R25-7-20250124","doi-asserted-by":"crossref","first-page":"857862","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"},{"key":"R26-7-20250124","doi-asserted-by":"crossref","first-page":"497503","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression.","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"key":"R27-7-20250124","doi-asserted-by":"crossref","first-page":"530534","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cellautonomous mechanism.","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"R28-7-20250124","doi-asserted-by":"crossref","first-page":"381394","DOI":"10.1517\/13543784.2011.541154","article-title":"Current and future directions in mammalian target of rapamycin inhibitors development.","volume":"20","author":"Fasolo","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"R29-7-20250124","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1159\/000319548","article-title":"Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.","volume":"79","author":"Kim","year":"2010","journal-title":"Oncology"},{"key":"R30-7-20250124","doi-asserted-by":"crossref","first-page":"396398","DOI":"10.1016\/j.jhep.2010.08.038","article-title":"mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.","volume":"54","author":"Waidmann","year":"2011","journal-title":"J Hepatol"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22434","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201201000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:15:05Z","timestamp":1737738905000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201201000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22434","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}